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Abstract
Type two diabetes mellitus is a highly prevalent disease for which the mechanism of
insulin signaling to initiate glucose uptake in cleaving TUG-UBL1 by the protease Usp25m is
currently not well understood. As increased insulin resistance can lead to the development of
type one insulin deficient diabetes, the knowledge of this pathway may uncover underlying
causes of insulin resistance. This research aims to understand the effect and stoichiometry of
Usp25m binding to TUG-UBL1 in relationship to the cleavage of TUG-UBL1 initiating
translocation of GLUT4 glucose transporter. The action of protease effector PIST will be
investigated to understand the importance of order in protein presence to initiate TUG-UBL1
cleavage. The mechanism of PIST action on TUG-UBL1 Usp25m protease will be elucidated to
understand the cascade of insulin signaling effects on glucose uptake. The understanding of this
mechanism will allow for investigation of this mechanism in relationship to a novel therapeutic
pathway in insulin resistant diabetes treatment. Current diabetes medications do not directly
impact the cellular uptake of glucose but negate the negative symptoms of insulin resistance,
while a therapeutic targeting this cleavage pathway can bypass insulin stimulation to reduce
increased insulin resistance. The specific description of this mechanism allows for therapeutic
small molecule investigations to stimulate or replace PIST action on Usp25m to artificially
trigger glucose uptake for diabetes treatment.
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Background
Prevalence Of Diabetes
Diabetes is a disease that has plagued the American population with increasing prevalence
in recent years. Type two diabetes mellitus is one of the most imperative medical challenges of the
21st century due to the overconsumption of relatively inexpensive, calorie dense, and highly
palatable food that is not satiating. This overconsumption has led to unprecedented increases in
obesity which is marked by the combined prevalence of diabetes and prediabetes at 50% of the
population in the United States,13 where obesity related type two diabetes mellitus (DMII) accounts
for 90-95% of diagnosed diabetes in adults.14 This increased prevalence in the US population
places youth at high risk of diabetes diagnosis and development of health problems as diabetes is
a lifelong illness which results in long-lasting side effects if not properly managed.
The lifelong impacts of diabetes include hyperglycemia which is marked by the excessive
glucose concentration in blood. Hyperglycemia is medically classified as increased blood glucose
concentration from the baseline concentration and often leads to long term damage, dysfunction,
and failure of organs especially in the eyes, kidneys, nerves, heart, and blood vessels15, 16 which
can lead to severe health conditions. Hyperglycemia is associated with symptoms of extreme thirst,
frequent urination, tiredness, nausea, and dizziness though extremely high blood sugar levels have
the potential to induce confusion or loss of consciousness leading many patients into a diabetic
coma. Further caution is required than the monitoring of hyperglycemia alone, as excess insulin or
insufficient
blood
glucose
concentration
can
cause
hypoglycemia. Hypoglycemia is
indicated by symptoms of racing
pulse, cold sweats, pale appearance
of the face, severe headache,
shivering or feeling weak at the
knees, restlessness or difficulty
concentration and can be serious if
sugar levels drop substantially.6, 17
The symptoms of hyper and
hypoglycemia are some of the first
indications of diabetes and in many
Figure 1. Patients diagnosed with diabetes in America cases the lack of immediate
from 1980-2014 with increasing prevalence.5
treatment causes severe health
impacts.
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Diabetes is classified in two categories
of type one and type two diabetes where type
two diabetes is also called diabetes mellitus type
two (DMII). Type one is classified by the
inability to produce insulin, while DMII is
metabolic resistance to insulin action.18 In
comparison to type one diabetes which requires
supplementary insulin treatment, DMII doesn’t
strictly necessitate the addition of insulin, but
rather close regulation of blood sugar levels as
insulin response is reduced or defective in this
type of patient.15 This resistance insulin results
in any insulin present in the blood not decreasing
blood glucose levels in the anticipated amount
from cellular glucose uptake. Once insulin
Figure 2. Glucose concentrations from high to
sensitization is limited to a certain extent, the
low blood sugar indicating hyperglycemia
release or supplementation of insulin becomes and
hypoglycemia
respectively.
ineffective at increasing cellular glucose uptake Corresponding
glucose
concentrations
and symptoms and signs of hypoinsulinism and relative to high or low glucose levels although
hyperglycemia appear, which are clinically definitive barriers between levels do not
6
recognized as diabetes mellitus.18 Diabetes exist.
mellitus is defined as insulin in the body having
no appreciable affect and cells acting in pathways that indicate the lack of insulin, therefore
exhibiting signs of hypoinsulinism. As such, differentiation of type one and type two diabetes
stems from the ability of the pancreas to produce insulin. Type one diabetic patients are physically
unable to secrete insulin though they are responsive to supplemental insulin, while DMII patients’
symptoms are due to inadequate response when the cells are stimulated by insulin15. Reduced
insulin response or sensitivity can lead to several health complications as insulin regulates the
absorption of glucose from the bloodstream to the cell to convert sugar into cellular energy. When
glucose is not adequately absorbed, blood glucose levels increase and result in symptoms
previously discussed due to the cells behaving in a starved state, where carbohydrate energy is not
available, and the cells must turn to catabolic processes to supplement the energy needed for cell
survival. DMII typically stems from obesity, though it can also be induced by the failure of glucose
metabolism, hypercholesteremia, hypertriglyceridemia, and arterial hypertension19 as well as
inherited genetic factors. As insulin is not an effective long-term treatment for patients with DMII,
alternative methods must be investigated in regulating blood sugar levels for individuals who do
not respond to insulin.
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Glucose as A Source of Energy and Carbon Fragments
The primary role of
glucose in the body is as an
energy and carbon source for
metabolism
of
several
important
biomolecules.
Glucose which enters the cell
via GLUT4 transport proteins
has two possible fates,
glycolysis as shown in figure
3, or glycogen synthesis. The
principal pathway of the two
fates is glycogen synthesis to
store energy for later use
which represents 75% of
glucose that enters the cell.
Figure 3. Glucose use in the cell to make nucleotides, amino This proportion of glucose
acids, and lipids prior to energy harvesting which takes place subject to glycogen synthesis
in the electron transport chain.9
supports the role of insulin as
an energy storage hormone as
glycogen synthesis is activated by insulin stimulation as a central method to decrease blood
glucose concentration.13 The energy stored and produced by glucose is essential in all cell
functions as glycolysis initiates the production of pyruvate which is used in many cell energy
pathways such as the citric acid cycle and supports the cellular growth and function of all cells in
the body. The carbon fragments produced from glycolysis are key regulators of many metabolic
pathways, and contribute to
the synthesis of nucleotides,
lipids, and amino acids, as
well as energy in the form of
ATP. This synthesis stems
from the carbon fragments
made throughout the TCA
cycle and energy made
available for cellular use in
the electron transport chain.9
Without glycolysis, the cell is
starved of necessary carbons
Figure 4. Insulin signaling by binding to the insulin receptor
to use for other biologically
subunit initiating a phosphorylation cascade resulting in
necessary pathways such as GLUT4 allowing for transport of glucose.8
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duplicating the genome utilizing nucleotides, and protein production utilizing amino acids. The
effect of insulin on adipose and muscle cells is initiated by the binding of insulin to the insulin
receptor subunit which causes a phosphorylation pathway to translocate a glucose transporter
protein GLUT4. GLUT4 is sequestered in glucose storage vesicles (GSVs) until insulin stimulation
is present. The translocation of GLUT4 allows for selective uptake of glucose dependent on
cellular needs.8 When insulin does not initiate the translocation of GLUT4, glucose is unable to
enter the cell for use in the biologically important process of producing energy and small carbon
fragments. Stimulation of this highly regulated metabolic process of glucose uptake occurs by
insulin binding to the insulin receptor on the membrane of adipose and muscle cells as shown in
figure 4. The reception of insulin causing signals across the cell membrane is a key mechanism in
the intensity and duration in insulin signaling and is commonly a major disfunction found to cause
DMII. This mechanism is a key element in allowing for glucose transport into the cell which is
mediated by GLUT4 transporters as seen in figure 4.20

Insulin as a Hormone
In contrast to most hormones which are small biomolecules functioning to regulate cellular
pathways, insulin is a polypeptide hormone controlling lipid and glucose metabolism produced by
the pancreas. To build this polypeptide hormone necessary to signal glucose uptake, insulin is
produced by beta cells in the pancreas regulated by glucose, amino acid, keto acid, and fatty acid
concentrations. This insulin is then secreted directly to the portal vein of the liver where up to 80%
of insulin is cleared to the bloodstream upon first
passage21 to be delivered by action of the heart. The
liver controls the output of insulin to the
bloodstream where it interacts with the adipose and
skeletal muscle cells as shown in figure 5 with the
general mechanism described in figure 4. Insulin
regulates blood glucose levels via the Na+dependent
and
Na+-independent
glucose
+
transporters, where only Na -independent
transporters can be affected by insulin stimulation.
Na+-dependent transporters are present in several
tissues such as epithelium and kidney cells where
they act in cotransport to absorb glucose by
coupling movement to Na+ into the cell. Thus, this
Figure 5. Insulin pathway through from process is dependent on extracellular and
production in the pancreas to uptake in intracellular ion concentrations which are
adipose and skeletal muscle cells to maintained by the Na+/K+ ATPase ion pump. In
degradation that occurs in the kidney.11
contrast, the Na+-independent glucose transporter
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family facilitates the movement of glucose down the concentration gradient across the plasma
membrane. Seven isoforms have been identified (GLUT1-7) although GLUT4 is the transporter
with highest concentration in insulin-sensitive tissues such as adipose and muscle cell tissues.
GLUT4 is the main glucose transport protein utilized in the insulin stimulation pathway to induce
glucose entry into the cell for use in energy producing and storage processes.22 After use in adipose
and skeletal muscle, insulin travels through the bloodstream to the kidney to be excreted.

Current Treatments
The deficiency in the uptake of glucose into the cell is the primary marker of DMII, as
previously discussed, and has been studied extensively. Insulin resistance can be clinically
determined with glucose and insulin injections while monitoring for blood glucose levels. The
magnitude that injected insulin suppresses hyperglycemia is monitored as lasting hyperglycemia
post introduction of insulin indicates that insulin is making little to no effect on glucose uptake on
the cellular level. When insulin is observed to not reduce blood sugar levels, this drastically
changes the treatment methodology from simply injecting insulin to the monitoring of blood
glucose levels. This analysis of insulin effect on blood glucose levels is highly essential to
differentiate between type one and type two diabetes. This differentiation is imperative as DMII
requires vastly different treatment from type one diabetes, as type one diabetes necessitates
supplemental insulin which is far less effective in treating DMII.
In treatment for insulin resistant DMII, many medications currently exist to assist with the
metabolic disfunctions caused by insulin resistance. One of the main mechanisms targeted is to
promote additional insulin secretion from the pancreas, commonly found in sulfonylurea
medications such as glimepiride and glipizide. Other medication mechanisms include increasing
insulin sensitivity such as in metformin, or binding to glycose to promote excretion through the
urine such as in Jardiance® and Farxiga®.
Several combined delivery medications also
exist, utilizing two or more of these mechanisms
to decrease diabetes related symptoms23 and
improve patient outcomes and quality of life.
Glipizide and glimepiride work similarly,
as both are in the class of sulfonylureas which
increase the amount of insulin molecules
secreted. This is done by stimulating the ATP
sensitive potassium channel in the pancreas to
induce partial closure of the channel with role
shown in figure 6. Sulfonylurea type Figure 6. ATP-dependent potassium
channel regulation of insulin secretion in
pharmaceuticals are typically used when interaction with sulfonylureas such as
pancreatic damage is not yet present due to glimpiride and glipizide which open the
progressed diabetes mellitus symptoms.24 This is KATP Channel.4
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shown in figure 6 depicting the action
of ATP sensitive potassium channels
in their regulatory role of insulin
release. Regulation occurs by the
stimulation of this ion channel to its
open form; this stimulation facilitates
increased amounts of insulin to be
released
to
the
bloodstream.
Sulfonylureas are extremely short
lived and require dosing before every
meal. The frequent dosing is
combined with side effects such as
Figure 7. Metformin activity in liver hepatic cells to
weight gain and hypoglycemia due to
decrease blood glucose concentration by reducing the
increased secretion of insulin that is
amount of glucose synthesized in the liver.4
not dependent on cellular conditions.
Both dosing regularity and side effects contribute to downfalls of this type of metabolic regulation
of glucose metabolism, while this medication also does not specifically solve the disfunction of
insulin stimulation not leading to glucose uptake.
Utilizing a different mechanism, altering carbon use in diabetic patients is performed by
medications in the biguanide class of which only metformin is approved for patient use. Metformin
targets the AMP dependent Protein Kinase (AMPK), where activation inhibits the ATP consuming
pathways of fatty acid synthesis and instead promotes ATP synthesis. This artificial low energy
state drives the insulin sensitive pathway towards glycolysis, and leads to reduced blood glucose
levels as glucose, although the exact mechanism remains controversial. Metformin enters the cell
and mimics increased AMP concentration which activates AMPK, therefore decreasing the
catabolic gluconeogenesis pathway, and increasing glycolysis to remove glucose from the
bloodstream. Activation of AMPK is regularly signaled by the decrease of cellular energy, marked
by increased AMP concentrations. This decrease of energy directs the cell by kinase activity
towards increased glucose uptake, fatty acid oxidation, and reduced gluconeogenesis as seen in
figure 7. The primary effect of this target is in hepatic liver cells which decrease systemic blood
glucose levels by the amount of glucose reabsorbed into the bloodstream. Lactic acidosis is
possible especially in patients who have liver disease, heart failure, kidney disease, sepsis, or
alcohol abuse.4
Jardiance and Farxiga target yet another pathway of decreasing diabetes mellitus effects on
the body, as both are inhibitors of sodium-glucose co-transporter 2 (SGLT2) which is responsible
for glucose reabsorption by the kidney as seen in figure 8. Inhibiting this reuptake pathway leads
to preferential excretion of glucose in the kidney through urine which then decreases the amount
of glucose in the bloodstream.14, 25 However, this method does not increase energy production in
patients on this medication and basis of treatment is on mitigation of hypoglycemia rather than in
allowing cells to uptake glucose. These treatments are typically reserved for patients who are not
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currently meeting glycemic target
levels with side effects such as genitourinary infection, hypotension, and
dehydration.
Even after a patient has been
diagnosed with diabetes mellitus and
several treatment options are available
for use, only about half of patients
achieve
recommended
glycemic
14
targets
which emphasizes the
necessity of medications with increased
efficacy in reaching glycemic target Figure 8. Sodium-glucose co-transporter 2 (SGLT2)
concentrations, especially in pathways inhibitor pathway to block glucose reabsorption into
7
which allow the cell to utilize the the blood by regulating kidney clearance. This
energy found in glucose. The lack of mechanism is utilized by SGLT2 inhibitors such as
Jardiance and Farxiga.
medications effective at reaching
glycemic concentrations which are desirable while bypassing the deficiencies in DMII
metabolism, lead to the necessity of diabetes medications which can act in place of insulin
sensitization and promote the usage of glucose as if insulin resistance was not present.
There is an overwhelming need for more effective and specific medications, especially as
current medications are focused on symptom-mitigation based solutions rather than circumventing
insulin stimulation. The major pathways utilized currently by pharmaceuticals include increasing
insulin sensitivity such as in metformin, although off target effects are likely when the target kinase
is found throughout the body. Other pharmaceutical treatments allow for increased elimination of
glucose, which prevent the additional buildup of side products which induce health effects.
However, these pathways do not mitigate the disfunction in insulin signaling found in diabetes
type two, as seen in SGLT2 inhibitors like Jardiance and Farxiga, as well as KATP channel
activators such as glipizide and glimpiride. The focus of these medication pathways is on
increasing glucose clearance which increases the danger of induced hypoglycemia and
hypotension. The ability to use rational design of pharmaceuticals necessitates highly specific
interaction of a medication with only the insulin stimulation pathway in a way that could not induce
further damage due to overproduction of insulin or negate the cell’s ability to uptake glucose. The
possibility of circumventing the requirement of insulin to uptake glucose would be highly
beneficial for patients who have progressed insulin resistance with or without damaged ß-cells.
A newly developed pharmaceutical with high specificity to the insulin signaling pathway
has the possibility to bypass side effects due to off target interactions. Additionally, a therapeutic
with this degree of specificity maintains the ability to bypass insulin stimulation, which mitigates
the risk of further insulin resistance, while additionally allowing the cell to utilize energy available
in the form of glucose found in the blood.
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Mechanism of Insulin Stimulation

Essential mechanisms in the insulin stimulation pathway are most notably PI3K
(phosphoinositide-3-kinase), which initiates the phosphorylation of PIP2 (phosphatidylinositol4,5-biphosphate) to PIP3 (phosphatidylinositol-3,4,5-triphosphate). This phosphorylation is
upstream to the signaling pathway which releases GLUT4 from sequestration and allows for
glucose uptake as seen in figure 9. Experimental disabling of this pathway removes insulin
stimulation effects, which supports the idea that PI3K is an essential node in insulin stimulation.
This is as PDK1 (phosphoinositidine dependent kinase 1) is affected by the production of PIP3
and Akt is one of the most common readouts associated with successful insulin stimulation.13
Pharmacological activity that does not require the use of PI3K has great potential to negate the
metabolic dysfunction found in DMII, and could be a successful replacement or supplement of
insulin injections. The necessity to bypass P13K indicates the advantage of targeting TUG-UBL1,
as this protein is downstream of PI3K action. Additionally, AMPK (AMP activated protein kinase)
is a currently targeted kinase in diabetes medication, which has uses in many metabolic processes
that could be disturbed with activation of energy building pathways to disfavor energy utilizing
pathways. This disruption has many implications in biological system feedback of ATP
concentrations and the body’s need for energy.
In the pathway of insulin stimulation, insulin initiates the cleavage of a Tether containing
UBX domain for GLUT4-Ubiquitin like 1 (TUG-UBL1) through a series of second metabolites
which promotes GLUT4, a glucose transporter, translocating to the cell surface which enhances
glucose uptake.26 Stimulation from insulin causes TUG-UBL1 to release GLUT4 molecules from
within a GSV (GLUT4 storage vesicle). GSVs are tethered to TUG-UBL1 utilizing IRAP (insulin
responsive aminopeptidase) to assist location of GLUT4 inside GSV on the N-terminal region as
shown in Figure 9 in the far-left cluster. Release of GLUT4 occurs by cleavage of the N-terminal
region from the C-terminal region of TUG-UBL1 which induces uptake of glucose through the
Figure 9. Insulin signaling secondary
messenger pathway. TUG; Tether
containing UBX domain for GLUT4,
IRS; insulin receptor subunit,
PI3K; phosphoinositide-3-kinase,
PIP3;
phosphatidylinositol-3,4,5triphosphate, PIP2; phosphatidylinositol4,5-biphosphate,
PDK1;
phosphoinositidine dependent kinase 1,
AMPK; AMP activated protein kinase
GAP; Rab GTPase Activating Protein,
IRAP;
insulin
responsive
aminopeptidase, PIST: syntaxin-6interacting protein, USP25m; protease
cleaving TUG, GSV; glucose storage
vesicle. Adapted1-3
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GLUT4 transporter. This cleavage of TUG-UBL1 stimulates the release of GLUT4, a glucose
transport protein, to the cellular membrane from GSVs in the golgi matrix and allows for the uptake
of glucose.26
As shown in Figure 9, the process of GLUT4 translocation is initiated by the binding of
insulin to the insulin receptor subunit (IRS). IRS is comprised of two extracellular 𝛼𝛼-subunits
binding to insulin, and two membrane spanning ß-subunits that each contain a tyrosine kinase
domain that allows initiation of second messenger signaling. The binding of insulin to the 𝛼𝛼subunit initiates the phosphorylation of tyrosine residues in the ß-subunit which recruits P13K
heterodimer and initiates a phosphorylation cascade of second messenger signaling. The P13K
heterodimer catalyzes the phosphorylation of PIP3 from PIP2.13 The phosphorylated PIP3 recruits
Akt to PDK1 which then phosphorylates Akt (serine-tyrosine kinase) and dephosphorylates PIP3
to PIP2 to recycle this phosphate carrier. Phosphorylation of GTPase activating protein (GAP) is
initiated utilizing AS160 (Akt substrate 160 kDa) which controls vesicle trafficking with by
phosphorylating a Rab6a GTPase activating Protein (GAP)2. AMPK is an AMP dependent protein
kinase and is an essential kinase utilized in many metabolic pathways to signal the need of
immediate ATP production and has previously been targeted in pharmaceutical investigations for
DMII treatment. In the case of glucose, AMPK demotes glycogen synthesis and deactivates fatty
acid oxidation which is catabolic and uses energy. AMPK is naturally stimulated by heightened
concentrations of AMP, the depleted form of ATP, indicating that immediate energy is needed and
to cease energy expenditure, which initiates the breakdown of glucose to produce ATP.
The mechanism of GAP activity on TUG-UBL1 and activation of USP25m protease is
thought to be by PIST (syntaxin-6-interacting protein) which is yet to be confirmed as an effector
of GAP proposed to stimulate TUG-UBL1 cleavage. Intact TUG-UBL1 links GSVs (glucose
storage vesicles) to the GSV by binding GLUT4 and IRAP (Insulin responsive aminopeptidase)
through its N-terminus and Golgin-160 and other matrix proteins by its C-terminus region. TUGUBL1 cleavage by USP25m protease separates these N and C termini and allows for TUG-UBL1
to guide GLUT4 from GSVs to the
cellular membrane. This movement
allows for glucose uptake into the
intracellular matrix for use in
glycolysis as seen in figure 10.2
The
dysfunction
of
phosphorylation kinases throughout
the insulin stimulated pathway leads
to insulin resistance, especially as the
cascading effect of GSV containing
GLUT4 vesicles translocation to the
membrane must be initiated, as this Figure 10. TUG interaction of GLUT4 and GSV utilizing
mechanism is utilized to continue cleavage by the Usp25m protease 2allowing for
translocation of GLUT4 to the cell surface.
glucose
uptake
after
initial
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translocation has occurred.2 If insulin-stimulated translocation of GLUT4 is not occurring as
necessary, the uptake of glucose is not possible without therapeutic intervention. Many hypotheses
exist of the methods of dysfunction in this pathway, ranging from dysfunction in phosphorylation
pathways13 to the USP25m protease2 with hypothesized mechanism shown in figure 10. Athough,
it is known that the function of this protease is essential to effectively uptake glucose from the
bloodstream. This allows for a mechanism to evade diabetes type two kinase mutations by way of
avoiding the insulin sensitive pathway and instead initiating the effects necessary from this
pathway to uptake glucose.

Failure of Insulin Response in Type Two Diabetes
Additional implications of insulin resistance are of the phenomena where existing insulin
resistance can cause the decrease of insulin production and secretion. The decrease in insulin
production is due to residual increased blood glucose levels after insulin has been secreted from
ß-cells in the pancreas, which leads to cell stimulation of synthesizing more insulin. As ß-cells
continue to synthesize insulin in attempts to lower blood glucose levels, the cells become fatigued
when no change results, and insulin production can fail as cytokine immune reaction to fatigued
ß-cells mount. With repeated or prolonged failures, the ß-cells will be depleted to the point of no
longer having the capacity to synthesize insulin which can lead to development of insulin deficient
type one diabetes27 from chronic type two diabetes. Increased insulin resistance resulting in
decreased secretion implies that therapies that circumvent the direct stimulation of insulin would
be highly beneficial in patients with DMII. This is due to the relationship of decreased insulin
secretion potentially resulting in long term insulin resistance as ß-cells become fatigued. If a
pharmaceutical is designed to circumvent this signaling, the decreased secretion of insulin could
be prevented in patients who have not yet lost production of insulin. As the stimulation of insulin
results in translocation of GLUT4 to the cell membrane, a singular event of endoproteolytic
cleavage is proposed to continue the uptake of glucose after the cleavage has occurred. As glucose
uptake is not stoichiometrically related to endoproteolytic cleavage, a pharmaceutical that
stimulates cleavage indicates a high potential for a small amount of pharmaceutical needed to
decrease blood glucose levels. This contrasts with currently prescribed medications where high
concentrations are necessary to stabilize blood sugar levels, leading to large and frequent doses
prescribed in DMII treatments.
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TUG-UBL1 includes a UBX
binding domain to GLUT4 in the Nterminal region as seen in Figure 11. This
region is intact in fasting cells and is
dissembled in the presence of insulin
stimulation, as seen in 3T3-L1 adipocytes.
It is hypothesized that TUG-UBL1 is a
tether protein to GSV that allows for
release and translocation of GLUT4 to the
cell membranes by disrupting the bond
between GLUT4 and TUG-UBL1. This
binding between TUG-UBL1 and GLUT4
is found in the N-terminal region of TUGUBL1, while the C-terminal region
Figure 11. Protein structure of TUG-UBL1 as remains attached to the mitochondrial
rendered from PDB 2AL3 with final three amino membrane and is necessary to retain
acids of N-terminus colored blue and C-terminus GLUT4 intracellularly. The disruption of
colored green.12
the N-terminal region allows for migration
2
of GLUT4 to the cell surface along a microtubule . Endoproteolytic cleavage of TUG-UBL1 is
shown to be necessary in translocation of GLUT4 transport proteins from GSV, which encapsulate
a pool of GLUT4 near the TUG-UBL1 protein. Endoproteolytic cleavage separates the N-terminal
region from the C-terminal region of TUG-UBL1, which allows for the release of GLUT4 from
the GSV to the plasma membrane.3 The protease Usp25m is required to stimulate this
endoproteolytic cleavage of the N and C-termini of TUG-UBL1, and is likely the protease
regulated by the insulin signaling pathway to release GLUT4 from GSV to the plasma membrane.
This interaction has been shown utilizing dose-dependent cleavage of TUG-UBL1 with GLUT4
upon increasing concentrations of Usp25m in 3T3-L1 adipocytes and is hypothesized to occur via
the same pathway in muscle cells.2
To determine the relationship of TUG-UBL1 in the protein interaction of glucose uptake
by an effector molecule of GAP, PIST, transgenic mice were formed utilizing a truncated TUGUBL1 protein that inhibits the suppression of GLUT4 in the golgi body. As knockout TUG-UBL1
mice causes embryonic lethality, UBX-Cter mice were formed where the UBX-Cter protein causes
depletion of PIST and mimics the insulin stimulated state. The transgenic mice had increases in
whole-body glucose turnover and overall metabolic rate.3 The study found that TUG-UBL1
definitively allows for movement of GLUT4 onto cell surfaces and that this action closely
mimicked the symptoms of diabetes type one which indicates the necessity of TUG-UBL1 and
PIST in the uptake of glucose to the cell.
The mechanism of TUG-UBL1 in response to insulin stimulation is still not fully
understood, though the potential of pharmaceutical interactions in this pathway includes the
possibility of inducing endoproteolytic cleavage. This cleavage would induce GLUT4

16
translocation possibly by activating PIST to act on the TUG-UBL1 protein. It is necessary to study
both interactions to find the most promising pharmaceutical mechanism to promote GLUT4
translocation without necessitating the addition of insulin. Additionally, as PIST could activate
Usp25m though the mechanism of this activation has not been determined, the interactions of PIST
and Usp25m will be studied to further understand the most essential target of pharmaceuticals.
This target will circumvent the insulin signaling pathway with the least off target effects as
possible. Since TUG-UBL1 is specific to the GLUT4 translocation pathway, this protein is a prime
target for highly specific pharmaceutical action and is anticipated to have little to no off-target
activity when a pharmacophore is designed specifically for this function as seen in several
approved rational design pharmaceuticals on the market.
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Proposal
It is imperative to bring a therapy to market that circumvents the insulin signaling cascade
for resistant patients by stimulating a specific mechanism in the insulin response pathway to
initiate glucose uptake independent of cellular insulin response. It has been shown that TUG plays
a central role in the insulin signaling pathway although the mechanism is not fully understood.
TUG cleavage is dependent on a phosphorylation pathway where Usp25m interacts directly with
TUG to cleave the protein and translocate GLUT4 for glucose uptake. TUG-UBL1 is an essential
protein, as cells with disabled TUG action do not uptake glucose upon insulin stimulation. To
allow such a target to exist, the mechanism must be fully elucidated for specific targeting of
effector molecules in a novel pathway.
To translocate GLUT4 storage vesicles to the cell surface, TUG must be acetylated to form
TUG ubiquitin-like modifier with N and C termini separated. To initiate this conformational
change, insulin in the bloodstream binds to the insulin receptor subunit resulting in a
phosphorylation cascade to release syntaxin-6-interacting protein (PIST) from the GAP regulator
protein. PIST affects TUG activation through the USP25m protease, as data supports Usp25m
association with unstimulated TUG-bound GSVs, and insulin stimulates the acute mobilization of
Usp25m from the TUG C-terminus.2 Upregulation of Usp25m has been shown to cleave TUG with
visible 42kDa and 54kDa products of the C-terminal region and 130kDa from the N-terminal
region. PIST has been shown to bind to TUG, though the effect exhibited to GLUT4 translocation
requires further study.2
The investigation of how PIST effects the endoproteolytic cleavage of TUG by activating
or deactivating Usp25m is the next step to further understanding the role of PIST mediation of
glucose uptake. This increased understanding in the insulin sensitive pathway allows for a
fundamental shift in diabetes related treatment discovery as a potential therapy of this sort would
be the first of its kind to allow for insulin independent treatment to decrease blood glucose levels
while allowing cells to utilize glucose for energy production.
TUG cleavage will be
monitored
utilizing
MALDI/MS (Matrix Assisted
Laser
Desorption/Ionization
mass spectroscopy) which is a
key technique in mass
spectroscopy
related
proteomics due to its extreme
Figure 12. MALDI/MS peaks anticipated in bound and nonsensitivity, ease of application bound products. Black represents uncleaved products of
and
tolerance
to unbound TUG-UBL1 (30kDa), unbound Usp25m (130kDa),
28
MALDI/MS and bound TUG-UBL1-Usp25m (160kDa). Red represents
contamination.
is another form of mass cleavage products at 42kDa, 54kDa, and 140kDa.10
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spectroscopy which ionizes compounds into charged molecules which mass/charge ratio is read in
a concentration dependent peak size. In MALDI/MS, peptides are separated into charged
molecules in a “soft ionization” method where ion formation does not significantly impact sample
integrity and is highly applicable for large polypeptide detection. An expected readout will be of
approximately the full polypeptide size due to this soft ionization methodology. MALDI/MS is
useful in purified proteins or intact cells where the size of protein products and concentration are
accurately monitored.29 This method is highly sensitive to protein confirmation and degradation
changes which is highly useful in the screening of protease effect on TUG cleavage due to the size
and concentration of cleavage products as analyzed by MS shown in figure 12.
First, the binding ratio of TUG and Usp25m protease will be determined and observed for
binding and cleavage affects using MALDI/MS, then the effect of PIST on cleavage will be
analyzed with MALDI/MS while varying concentration of PIST and time of addition. This will
elucidate the mechanism by which TUG cleavage is controlled to allow for further pursuit into
pharmacological target proteins.

Aim 1: Determination of Usp25m Concentration Necessary to Bind TUGUBL1.
Currently, it is known that USP25m binds to unstimulated TUG protein and the
dissociation of this protease is related to the cleavage of TUG into its N-terminal and C-terminal
products. This phase will determine the effects of USP25m concentration on TUG cleavage to find
the necessary cellular concentration of protease to initiate cleavage. This cleavage will be
monitored utilizing MALDI/MS as previously discussed.
Expected results of un-cleaved product will show bound TUG-Usp25m at 140kDa with
100% integration area and no peak area found in 42, 54, and 140kDa from cleavage products as
seen in figure 12. When Usp25m effectively initiates cleavage, peaks are anticipated only at 42,
54, and 140 kDa with little to no area at 160kDa showing only cleavage products without the fulllength TUG-Usp25m complex. Additionally a SDS-PAGE gel will be run on TUG protein product
after treatment with varying concentrations of protease USP25m to determine if cleavage products
of 42 and 54 kDa from the C-terminus and 140kDa from the USP25m bound N-terminus are
present in relative abundance to full length TUG protein of 60kDa and free USP25m of 130kDa.2
MALDI/MS will provide sensitive quantitative analysis of USP25m concentration needed to
initiate TUG-UBL1 cleavage as shown in Figure 9 while SDS-PAGE will provide a reliable and
qualitative reference to MALDI/MS for further confirmation of results. Optimal molar ratio of
Usp25m will determine the least unbound Usp25m by monitoring of 130kDa peak through trials
of altered Usp25m concentration added and allows for further study of the TUG cleavage
mechanism without free Usp25m confounding results.
The cleavage of TUG-UBL1 dependent only on USP25m will further determine the effect
of this protease without external stimulation in fetal bovine serum which mimics basal cellular
activity and is expected to remain in un-cleaved form when bound to only Usp25m. When insulin
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stimulation is not present, USP25m surrounds TUG although a baseline activity of protease effect
on TUG confirmation is needed to determine further interactions of USP25m and TUG. This is
necessary to monitor the effects of this protease for diabetes related treatments, as well as a more
in-depth analysis of the bio-functionality of this process.
Experimental techniques will mimic the
scheme shown in figure 13. TUG-UBL1 will
be obtained from 3T3-L1 adipose cells
transfected by retroviruses to induce the
expression of TUG in plasmids created by the
Bogan lab30 which will be grown in E. coli to
utilize regulation from lac-operon induced
production of TUG with IPTG31 prior to
purification utilizing a Q-sephadex anion
exchange column as done by Singh et. al.32 to
remove cell debris and non-target proteases
present in the E. coli vehicle. Separation will
be verified utilizing SDS-PAGE gel as TUG
protein from this plasmid will be 60kDa and
Figure 13. Scheme of experimental techniques Ovalbumin and Myoglobin can be used as
to determine TUG-Usp25m molar ratio of markers with relative sizes of 44.5kDa and
binding.
17kDa respectively.
USP25m will be obtained utilizing procedures and plasmids from the Denuc lab with
purification of USP25m protease performed utilizing a Ni2+ pull down column to remove residual
proteins from E. coli growth for use in TUG-Usp25m binding molar ratio determination.33
Utilizing a method developed by Tucher et. al., the purified TUG protein will be added increasing
concentrations of USP25m in fetal bovine serum to closely mimic cellular conditions while
utilizing in vitro control as done by Habtemichael et. al.2 and allowed to react prior to the addition
of sodium carbonate to irreversibly inactivate protease activity. Samples will then be loaded into
16% SDS-PAGE gel34 with myoglobin, myosin, and ovalbumin markers and relative isoform
concentrations validated with MALDI/MS, utilizing analysis methods devised by Parker et. al.10
without chromatography monitoring of protease activity due to the lack of antibody affinity beads
specific for the GLUT4 binding location of TUG. Increasing Usp25m concentration will elucidate
the necessary molar ratio to ensure the minimum possible amount of free Usp25m for use in
effector activity studies. It is desired to have the highest concentration of bound TUG-Usp25m
with minimal free TUG or free Usp25m to best understand the mechanistic effect in future
investigations.
The binding of USP25m in increasing concentration will be determined by the concentration
of free un-cleaved TUG protein at 30kDa, bound USP25m TUG protein at 160kDa, and monitoring
of cleavage side products at 42, 54, and 130kDa which are not expected in TUG-Usp25m bound
molecules without effectors added. If the reaction runs as expected the binding of USP25m will
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not induce cleavage regardless of added concentration as an affecter necessity is anticipated to
separate TUG-USP25m and induce proteolytic cleavage of the TUG protein resulting in Nterminal and C-terminal products. The molar ratio concentration of USP25m which best binds
TUG protein will be utilized in following experimentation to determine PIST affect in proteolytic
cleavage in bound TUG-USP25m.

Aim 2: Investigation of PIST Activity on Usp25m to Regulate TUG
Cleavage.
To determine the effect of PIST on the TUG-USP25m complex, PIST will be grown
and separated following the scheme shown in figure 14 utilizing a method developed by Wente et.
al. with transfection of pAS2 vector containing PIST plasmid transfected in HEK293 cells grown
on poly-d-lysin-coated glass covered slips. Cells will then be lysed in assay-lysis buffer prior to
centrifugation. Further purification will be performed utilizing a Glutathione-affinity column pulldown assay utilizing His6-tag fusion protein to bind PIST.35 Purification of PIST proteins will be
monitored by SDS-PAGE with expected size of 28kDa and concentration determined by
MALDI/MS with experimental method utilized as previously described. If purification of PIST is
not achieved utilizing this method, pre-purified protein ab93743 will be purchased through
abcam,35 though this product may not be compatible for MALDI/MS analysis due to its purity and
higher stability than proteins recently made by the
vehicle. If proteases are degraded while trials are in
place, the experiment will need alteration to match
cellular conditions more concisely. In an event that
MALDI/MS is ineffective at monitoring cleavage
products, it may be necessary to determine
mechanistic abilities although fluorescent tagging
will likely be necessary to monitor the cleavage
products which reduces quantitative ability to monitor
PIST affect.
The determined most effective molar ratio
binding concentration of USP25m to 50mM TUG will
be utilized to further investigate the effect of PIST on
the TUG cleavage product. Two variables of PIST
concentration and order of PIST combination will be
analyzed, with increasing concentrations added to
pre-described sample combinations. PIST will be Figure 14. Experimental scheme of
added to 50mM TUG bound USP2m with optimal techniques used to determine order of
molar ratio in fetal bovine serum as discussed addition of PIST to Usp25m and TUG to
previously and analyzed in 16% SDS-PAGE to determine cleavage effects.
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determine cleavage products.
The PIST added to TUGUSP25m complex will be
compared to a subsequent
assay with USP25m combined
with
increasing
Figure 15. Cleavage monitoring of TUG in C-terminal region concentrations of PIST prior
in presence of insulin with mutated TUG short hairpin RNA
to addition to TUG to form
sequence mutations to show SDS-PAGE expected results when
any PIST-USP25m complex
USP25m protease cleaves TUG protein.3
prior to TUG protein
interaction. The comparison of these assays will determine if PIST binds to USP25m prior to TUGUSP25m complex formation or if PIST initiates the separation of an already bound TUG-USP25m
complex. The impacts of this order of binding will bring understanding of the interaction of PIST
and Usp25m, as it is possible for Usp25m binding to TUG prevented by PIST which would allow
for cleavage over time, or for PIST to remove Usp25m from TUG inducing cleavage. Cleavage of
TUG will be analyzed by MALDI/MS for concentration determination and SDS-PAGE gel to
visually monitor protease activity based on N-terminal and C-terminal products of protease
cleavage as shown below in figure 15 where determinations of proteolytic ability were tested in
short hairpin RNA (shRNA) modifications of TUG. If activity does not increase with
concentration, protein specificity may need to be further confirmed utilizing western blot to ensure
the correct protein is purified in a cellular stable conformation.
The tracking of TUG cleavage dependent on PIST addition before or after USP25m
protease and PIST concentration increases understanding of the signaling cascade initiating TUG
cleavage and allows for glucose uptake due to GLUT4 translocation. This mechanism is necessary
to fully discern prior to any pharmaceutical developments for effective DMII treatment. Other
known negative regulation pathways of USP25m have been described, such as in IL-17 signaling
pathways with roles in inflammation.36 However, the regulation of Usp25m in the TUG-insulin
signaling pathway mechanism regulated by GAP protein release of PIST suggests PIST is a
positive regulator of USP25m cleavage. As such, this quantification of PIST effect on USP25m
cleavage is necessary to elucidate the mechanism of action which PIST contributes to the insulin
signaling pathway leading to glucose transport into the cell. It is known that USP25m exists in the
presence of unstimulated TUG-UBL1 and is related to the cleavage of TUG to its products,
although the direct effect of PIST released from the GAP mediator protein is not well understood.
Greater understanding of this mechanism will be gained by altering the order of products added,
allowing elucidation of PIST as a Usp25m inhibitor to prevent Usp25m-TUG binding or as an
initiator of cleavage on the TUG-Usp25m complex. Further understanding of the TUG-UBL1
cleavage pathway in respect to USP25m protease action based on presence of PIST will enhance
understanding of the pathway to initiate cellular glucose uptake. This increased understanding
allows further experimental determinations to be made on possible treatment mechanisms for type
two diabetic patients who have greatly reduced responses to insulin stimulation.
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